Non-invasive, bedside assessment of systemic endothelial function: a predictor of mortality in intensive care?

Submission date	Recruitment status No longer recruiting	Prospectively registered		
19/05/2009		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
05/06/2009	Completed	[X] Results		
Last Edited	Condition category	☐ Individual participant data		
29/01/2013	Haematological Disorders			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Brian Mullan

Contact details

Regional Intensive Care Unit Royal Victoria Hospital Grosvenor Road Belfast United Kingdom BT12 6BA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

RGHT000413

Study information

Scientific Title

Function of the Endothelium in Critical Care: a prospective observational cohort study

Acronym

FECC

Study objectives

Bedside assessment of systemic endothelial function using non-invasive pulse wave analysis (PWA) predicts outcome in intensive care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Northern Ireland HPSS REC 3 approved on the 21st June 2007 (ref: 07/NIR03/30)

Study design

Prospective observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Systemic endothelial function in critical care

Interventions

Recruited patients will be categorised as follows:

- 1. Medical
- 2. Surgical
- 3. Trauma
- 4. Burns

Baseline information to be recorded will include:

- 1. Patient demographics
- 2. Physiological data

- 3. Plasma biochemistry profile (including liver function)
- 4. Full blood picture and coagulation screen
- 5. Acute Physiology and Chronic Health Evaluation II (APACHE II) score
- 6. Simplified Acute Physiology Score II (SAPS II) score
- 7. Sequential Organ Failure Assessment (SOFA) score

All clinical data and measurements will be undertaken and recorded by the research fellow. Systemic endothelial function as measured by pulse wave analysis will be performed noninvasively using the SphygmoCor™ pulse wave analysis system (AtCor Medical Pty Ltd, Australia). In addition the following surrogate markers of endothelial function will be recorded:

- 1. Albumin creatinine ratio (ACR)
- 2. Plasma von Willebrand Factor (vWF)
- 3. Plasma adhesion molecules, ICAM, VCAM and E-selectin

Blood and urine samples will be taken at admission. Urinary albumin and creatinine concentrations will be measured by ELISA and colorimetric assays, respectively. Von Willebrand Factor and adhesion molecules, ICAM, VCAM, E-Selectin will be measured using an ELISA. A blood sample will be taken 20 minutes after administration of the nebulised salbutamol. This sample will be analysed for a plasma salbutamol concentration, again using ELISA. In this way systemic uptake of salbutamol will be confirmed.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Intensive Care Unit (ICU) mortality

Secondary outcome measures

- 1. Length of ICU stay
- 2. Number of ventilator days
- 3. Incidence of organ failures
- 4. Need for continuous renal replacement therapy
- 5. Duration of inotropic support

Overall study start date

01/07/2007

Completion date

01/12/2009

Eligibility

Key inclusion criteria

All adult patients admitted to the regional intensive care unit at the Royal Group of Hospitals, Belfast will be eligible for inclusion in the study.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

182

Key exclusion criteria

- 1. Aged less than 18 years old
- 2. Pregnancy
- 3. Inability to achieve radial arterial access
- 4. Known allergy or sensitivity to salbutamol or glyceryl trinitrate (GTN)
- 5. Patients transferred from other intensive care units
- 6. Patients unlikely to survive more than 24 hours
- 7. Patients with an advance directive regarding limitation of treatment
- 8. Patients who have a "Do Not Attempt Resuscitation" (DNAR) order in place
- 9. Lack of consent

Date of first enrolment

01/07/2007

Date of final enrolment

01/12/2009

Locations

Countries of recruitment

Northern Ireland

United Kingdom

Study participating centre Regional Intensive Care Unit

Belfast United Kingdom BT12 6BA

Sponsor information

Organisation

Royal Victoria Hospital (UK)

Sponsor details

Grosvenor Road Belfast Northern Ireland United Kingdom BT12 6BA +44(0)28 9024 0503 mary.williams@belfasttrust.hscni.net

Sponsor type

Hospital/treatment centre

Website

http://www.belfasttrust.hscni.net

ROR

https://ror.org/03rq50d77

Funder(s)

Funder type

Research organisation

Funder Name

Royal College of Anaesthetists/British Journal of Anaesthesia (UK) - Grant (2008)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2011		Yes	No